
---
title: '《狂犬病疫苗》狂犬病疫苗的有效性和持久性'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=706478'
author: 科学网
comments: false
date: Thu, 15 Apr 2021 08:00:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=706478'
---

<div>   
<h2 style="margin: 15px 0 23px;text-indent: 46px;padding: 0;line-height: 200%;background: rgb(255, 255, 255)"><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 24px">大型学术专著《当代新疫苗》（第二版）于去年</span></strong><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 24px">3月正式出版。</span></strong></h2><h2 style="margin: 15px 0 23px;text-indent: 46px;padding: 0;line-height: 200%;background: rgb(255, 255, 255)"><strong><span style="font-family: KaiTi;color: #0070C0;letter-spacing: 0;font-size: 24px"><span style="font-family:KaiTi">本人与中国食品药品检定研究院的李玉华研究员共同撰写了该书第</span><span style="font-family:KaiTi">40章《狂犬病疫苗》。</span></span></strong></h2><h2 style="margin: 15px 0 23px;text-indent: 39px;padding: 0;line-height: 200%;background: rgb(255, 255, 255)"><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px">本博客将分若干次全文转载这一章的内容。今天转载的是本章的第</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px">10</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px">节</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px">:</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px">狂犬病</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px">疫苗的有效性和持久性</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;color: #0070C0;letter-spacing: 0;font-size: 21px">。</span></strong></h2><p style="margin-top: 15px;margin-right: 0;margin-bottom: 15px;padding: 0;line-height: 200%;background: rgb(255, 255, 255)"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 29px">10　疫苗的有效性和持久性</span></strong></p><p><strong><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">10.1  </span></span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 24px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';color: #333333;letter-spacing: 1px;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">的有效性</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">细胞培养狂犬病疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(CCRV)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">的开发和广泛使用极大地提高了</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">的安全性和有效性</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(effectiveness)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。失败的狂犬病</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">仅发生在发展中国家的个别病人中，但是此类案例的大多数据报告都在某种程度上违背了</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">WHO</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">推荐的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">治疗方案</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(Rupprecht and Plotkin,2018)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。与</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">失败有关的原因包括：推迟寻求治疗、未进行或未适当进行首次伤口处理、未进行或未适当进行免疫球蛋白</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(RIG)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">接种、未浸润式注射</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RIG</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">就缝合伤口或狂犬病疫苗质量差。</span></span></strong></p><p style="text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 21px;background: #FFFFFF">10.1.1  CCRV</span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 21px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">效力的直接和间接证据</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">采用正确的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CCRV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">接种程序，可对几乎所有的健康受种者诱导足够高的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">滴度</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">≥</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">0.5 IU/mL</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">）。暴露前体内中和抗体滴度达到这一水平者无一例发生狂犬病</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(WHO,2005)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。在暴露于狂犬病病毒后，如能立即接种疫苗并正确处理伤口，且同时注射狂犬病</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RIG</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">，几乎可</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">100</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％地预防狂犬病发生，即便是在高危暴露的情况下也是如此。</span> <span style="font-family:KaiTi">如果</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">过迟或未能正确完成，就有可能导致死亡，尤其当咬伤部位神经密布，如头、颈部，或多处受伤时。</span> <span style="font-family:KaiTi">但如在接种完疫苗后能检测到抗体时还未发病，则以后再不会发病。</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">一些研究者为</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CCRV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">（必要时与</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RIG</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">联合使用）的效力提供了直接证据：据报道，有</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">47</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">名被患狂犬病的狗或狼咬过的患者在注射了</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">HDCV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">后，没有患狂犬病</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(Bahmanyar et al.,1976)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。</span> <span style="font-family:KaiTi">在泰国，在对皮内注射了</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PCECV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">113</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">名</span><span style="font-family:KaiTi">Ⅲ级暴露者进行了</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">年的随访，没有观察到狂犬病病例</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(Quiambao et al.,2005)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。</span> <span style="font-family:KaiTi">在进行了肌内或皮内接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PVRV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> <span style="font-family:KaiTi">的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">566</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">名被证实与患有狂犬病的动物接触过的泰国孩子中，没有发现狂犬病病例</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(Chutivongse et al,1988)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">同样，在我国有</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">171</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">名严重的狂犬病暴露患者在暴露后接种了</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PVRV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">，他们在</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">6</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">个月后仍存活。很多其他领域的研究也被用来对皮内或肌内接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PVRV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">在狂犬病病毒</span> </span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">中的临床效果进行评估。在各自的随访期间没有发现狂犬病病例（俞永新，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">2009)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。</span> <span style="font-family:KaiTi">大量的血清学研究为</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CCRV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">（必要时同时使用</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RIG</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">）的效力提供了间接证据。</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">迄今为止，在中和抗体浓度达到或高于</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">0.5 IU/mL</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">的个体中，从未报告过狂犬病病例。健康个体在完成了</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">WHO</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">推荐的免疫接种程序后，抗体滴度高于这个最低值时，实际上可达到</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">100</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％</span> <span style="font-family:KaiTi">保护（</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">WHO,2005)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。</span> <span style="font-family:KaiTi">已有足够的数据证实，暴露后如能及时局部处理伤口并及时按程序接种疫苗，可获得可信的保护效果。</span></span></strong></p><p style="text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 21px;background: #FFFFFF">10.1.2 </span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 21px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">判断狂犬病疫苗效力的简单实用的标准</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">实际上疫苗接种失败多数都出现在第</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">针开始后的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">20</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">天之内，主要是头面部被严重咬伤的患者。如果过了这个时间还未发病，以后再发病的可能性几乎不存在。</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">对患狂犬病的风险或疫苗效力可采用一个简单实用的判断标准：只要在发病前全程接种完了疫苗，产生了抗体，体内（包括</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CNS</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">内）就不可能再有狂犬病病毒</span><span style="font-family:KaiTi">“潜伏”，就不会再发病。</span></span></strong></p><p style="text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 24px;background: #FFFFFF">10.2  </span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 24px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">狂犬病疫苗的免疫持久性</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CCRV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">后，免疫记忆的发展是针对狂犬病在人体建立长期持久免疫的关键。</span> </span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">检测是确认狂犬病的暴露前预防</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(PrEP)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">或</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">后免疫反应的最简便方法。</span> <span style="font-family:KaiTi">关于病人初次接受疫苗接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(PrEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">或</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">）的剂量数与循环系统中</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">长期维持之间的关系，已进行了多项临床试验和回顾性研究</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(Hampson et al.,2011)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">在一项回顾性研究中，用</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">Kaplan Meier</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">生存分析来评估</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">875</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">名病人初次接受人二倍体细胞疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(HDCV)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">后抗体长期持续的情况。</span> <span style="font-family:KaiTi">病人分别经肌内途径</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(IM)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">或经皮内途径</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(ID)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">进行</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">3</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">剂</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PrEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">系列接种，或</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">5</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">剂</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(IM)PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">系列接种。</span> <span style="font-family:KaiTi">在初次接种后长达</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">9</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">年的时间里，未再接受加强注射，在不同时间间隔从病人获取血液样本进行测试。</span> <span style="font-family:KaiTi">结果显示，与经皮内途径接种疫苗的病人相比，循环系统中可检测到的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">在经肌内途径接种疫苗的病人中持续的时间较长，约</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">80</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％经肌内途径接种疫苗的病人在初次疫苗接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">9</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">年后依然可检出</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">滴度。</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">对体液免疫反应持续时间的评估，选择在</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">2</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">14</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">年以前已经进行过初次</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PrEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">或</span> </span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">系列接种的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">18</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">名曾使用</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">HDCV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">或纯化鸡胚细胞疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(PCECV)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">病人中进行。</span> <span style="font-family:KaiTi">研究结果显示，所有病人均有可检出的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">滴度，其中最早进行的初次疫苗接种是在</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">14</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">年以前。</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">已发表的资料表明，病人即使只进行了</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PrEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">或</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">的初次系列预防接种，而未在初次接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">年后再进行加强免疫接种，其循环系统中的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">持续的时间也相当长；对于接受了</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PrEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">初次系列疫苗接种，并在</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">年后进行了加强免疫接种的病人，有很多研究报告证明，他们体内已经获得了更长期的持续的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">另一项研究则证实，实行狂犬疫苗接种不会对其他疫苗的接种效果造成影响</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(Rupprecht et al.,2018)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 21px;background: #FFFFFF">10.2.1 </span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 21px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">疫苗加强接种后的免疫回忆反应</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">图</span><span style="font-family:KaiTi">2为预防性接种3针狂犬病疫苗，然后在１年后加强接种1～2针，所引发的中和抗体滴度变化示意图</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(Rupprecht and Plotkin,2018)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=706478" title alt="image.png" width="700" height="532" style="width: 700px; height: 532px;" referrerpolicy="no-referrer"> </span></strong></p><p style="margin-left:0;text-indent:42px;text-autospace:ideograph-numeric;line-height:200%"><span style=";font-family:Calibri;font-size:14px"> </span></p><p><strong><span style="font-family: SimSun;font-size: 19px">图２</span></strong><strong><span style="font-family: Calibri;font-size: 19px"> </span></strong><strong><span style="font-family: SimSun;font-size: 20px">疫苗基础免疫和加强接种后的中和抗体滴度变化示意图</span></strong></p><p><span style="font-family: SimSun;font-size: 19px">① </span><span style="font-family: Calibri;font-size: 19px">WHO</span><span style="font-family: SimSun;font-size: 19px"><span style="font-family:SimSun">定义的最小适宜滴度；</span> <span style="font-family:SimSun">② 美国</span></span><span style="font-family: Calibri;font-size: 19px">CDC</span><span style="font-family: SimSun;font-size: 19px">定义的最小适宜滴度（经许可引自</span><span style="font-family: Calibri;font-size: 19px">Rupprecht and Plotkin,2018)</span><span style="font-family: SimSun;font-size: 19px">。</span></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> </span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">从图</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">2</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">中可见，肌内接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">3</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">针（或</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">5</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">针）疫苗后，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">个月内中和抗体滴度高峰值平均可达</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">10 IU/mL</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。以后半年内先快速下降，随后缓慢下降，到第</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">12</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">个月时平均中和抗体滴度仍大于</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1 IU/mL</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。此时加强</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">2</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">针后，平均中和抗体滴度几乎是立即超过</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">20 IU/mL</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。有研究证明，加强免疫后</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">7</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">天，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">100</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">％</span> <span style="font-family:KaiTi">的受试者显示抗体水平升高</span><span style="font-family:KaiTi">5倍。</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">所以凡过去接种过</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">3</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">针（或以上）疫苗的接种者，再次暴露后加强接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">2</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">针即可。</span> <span style="font-family:KaiTi">而且凡以前接种过</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">3</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">针（或以上）疫苗者，以后永远没必要再接种狂犬病免疫球蛋白。有数据证明，超过</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">20</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">年前曾接种过疫苗者，再次加强的效果仍然非常好。</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">从图中可见，接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">3</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">针狂犬病疫苗后，半年内抗体滴度都远远高于最小适宜滴度，通常没必要检测抗体。加强接种后，有效保护期在</span><span style="font-family:KaiTi">3年以上。对于有感染狂犬病风险的人，如果后来暴露于狂犬病，有以下两个理由支持对他们进行暴露前免疫接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(PrEP)(WHO,2013)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">：</span><span style="font-family:KaiTi">① 在进行完整的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">时，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">2</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">剂疫苗的加强接种就能迅速引发免疫回忆反应，从而可减少疫苗剂量和就医次数；</span><span style="font-family:KaiTi">②不需要再接种狂犬病免疫球蛋白。</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">有免疫接种史个人的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">接种方案（</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">2</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">针方案）：对于先前应用细胞培养疫苗进行过全程暴露前或</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">的个人，无论过了多久，再次暴露后，只需在仔细进行伤口清洗和消毒后，分别于第</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">0</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">天和第</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">3</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">天给予肌内（或皮内）注射</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">剂疫苗就足够了。</span> <span style="font-family:KaiTi">所有进行加强接种的病例都不需注射狂犬病免疫球蛋白。</span> <span style="font-family:KaiTi">加强针剂可以肌内注射也可以在降低剂量的情况下皮内注射。</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">已发表的一些临床试验提供的数据确认，一个以前接种过疫苗的人会对</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">剂或多剂狂犬病疫苗的加强接种迅速产生反应，即使最初的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PrEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">或</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">系列接种是在几年前进行的；不管初始疫苗接种是通过肌内还是皮内途径；也不依赖于以前接种过疫苗的人是否还有可检测到的</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">RVNA</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">另一项研究指出，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">5</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">10</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">年前曾接受疫苗接种的病人与超过</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">10</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">年前接受疫苗接种的病人在再次接受加强免疫后，两者之间抗体水平没有显著性差异</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(Rupprecht and Plotkin,2018)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 21px;background: #FFFFFF">10.2.2 </span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 21px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">疫苗定期加强接种的适用对象</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">无论是出于暴露前或</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">PEP</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">的目的，已接受狂犬病疫苗全程基础免疫者都没有必要定期接种加强剂次。</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">定期进行加强接种仅推荐用于因职业原因而有持续、频繁或较高的风险暴露于狂犬病的人群</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(CDC,2008)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 21px;background: #FFFFFF">10.2.3 </span></strong><strong><span style="font-family: 'Microsoft YaHei UI';line-height: 200%;color: #333333;letter-spacing: 1px;font-size: 21px;background: #FFFFFF"><span style="font-family:Microsoft YaHei UI">定期进行加强接种的时机和方案</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">关于上述需要定期加强接种的适用对象，在初次接种后何时应当进行常规加强剂量接种的建议各不相同（</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">5</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">年）。然而，一些最近发表的临床试验表明，已接受</span> <span style="font-family:KaiTi">３～５剂狂犬病</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">CCRV</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">初次系列接种者，会有长达数十年的持久免疫，在加强接种后，可引发出更好的免疫回忆反应。</span> <span style="font-family:KaiTi">最近有一个相关的生存案例，该病人在不知情的情况下进行了肝移植手术，而肝的供体后来被确诊为狂犬病患者，该接受已感染肝移植的病人却存活了下来，而接受同一个供体另外两个肾和胰腺移植的人，都在移植手术进行后</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">3</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">周内死于狂犬病所致脑炎。进一步调查显示，该接受肝移植的存活者在童年时曾接种过狂犬病疫苗</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(Jackson,2013)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。</span></span></strong></p><p style="margin-left:0;text-indent:56px;text-autospace:ideograph-numeric;line-height:200%"><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">从事活狂犬病病毒相关研究或疫苗生产的人员，都应该定期（每隔</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">6</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">24</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">个月，具体视风险评估结果而定）检测抗体水平，以避免不必要的加强接种。仅当狂犬病中和抗体滴度低于</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">0.5</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> </span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">IU/mL</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">时，才推荐进行加强接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">(CDC,2008)</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">。实际上他们多数是在首次预防性接种</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">3</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">针疫苗后，</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">年后加强</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">针，以后每</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">3</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">～</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">5</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">年再加强</span></span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF">1</span></strong><strong><span style="font-family: KaiTi;line-height: 200%;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:KaiTi">针。</span></span></strong></p><p><span style=";font-family:SimSun;font-size:14px"> </span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:0;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: SimSun;color: #333333;letter-spacing: 0;font-size: 21px">相关博文：</span></strong></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:20px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1277395" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">《狂犬病疫苗》专著共享</span></span></a><span style="font-family: SimSun;color: #6666CC;letter-spacing: 0;font-size: 19px"> </span><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2021-03-18</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:20px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1277585" target="_blank"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著共享) 1. 概述</span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> </span><span style="font-family: SimSun;color: #666666;letter-spacing: 0;font-size: 19px"> </span><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px">2021-03-19</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:20px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1277814" target="_blank"><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著共享) 2.病原学</span></span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> </span><span style="font-family: SimSun;color: #666666;letter-spacing: 0;font-size: 19px"> </span><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px">2021-03-21</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:20px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1277951" target="_blank"><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著共享) 3.流行病学</span></span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2021-03-22</span><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1278323" target="_blank"></a></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:29px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><strong><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著) 4. 发病机理与疫苗免疫应答</span></strong><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2021-03-24</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:29px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1278633" target="_blank"><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著) 5. 狂犬病的症状和临床诊断</span></span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2021-03-26</span></p><p style="margin-top:16px;margin-right:0;margin-bottom:16px;margin-left:0;text-indent:29px;padding:0 0 0 0 ;line-height:28px;background:rgb(255,255,255)"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1279308" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=706468" title alt="image.png" style="color: rgb(102, 102, 102); font-family: Tahoma; font-size: 19px; text-indent: 35px; white-space: normal;" referrerpolicy="no-referrer"><span style="text-decoration:underline;"><span style="font-family: Tahoma;color: #6666CC;letter-spacing: 0;font-size: 19px"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著) 6. 狂犬病疫苗制造(A)</span></span></a><span style="font-family: Tahoma;color: #666666;letter-spacing: 0;font-size: 19px"> 2021-03-30</span></p><p style="margin-left:0;text-indent:35px;text-autospace:ideograph-numeric;line-height:200%"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1279597" target="_blank"><strong><span style="text-decoration:underline;"><span style="font-family: Tahoma;line-height: 200%;color: #6666CC;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著) 6. 狂犬病疫苗制造(B)</span></span></strong></a><span style="font-family: Tahoma;line-height: 200%;color: #666666;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> 2021-04-01</span></p><p style="margin-left:0;text-indent:35px;text-autospace:ideograph-numeric;line-height:200%"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=706468" title alt="image.png" style="color: rgb(102, 102, 102); font-family: Tahoma; font-size: 19px; text-indent: 35px; white-space: normal;" referrerpolicy="no-referrer"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1281048" target="_blank"><strong><span style="text-decoration:underline;"><span style="font-family: Tahoma;line-height: 200%;color: #6666CC;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著) 7-8. 狂犬病暴露后和暴露前的预防</span></span></strong></a><span style="font-family: Tahoma;line-height: 200%;color: #666666;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> 2021-04-09</span></p><p style="margin-left: 0px; text-indent: 35px; line-height: 200%;"><a href="http://blog.sciencenet.cn/home.php?mod=space&uid=347754&do=blog&id=1281683" target="_blank"><img src="https://cors.zfour.workers.dev/?http://bbs.sciencenet.cn/home.php?mod=attachment&filename=image.png&id=706468" title alt="image.png" style="color: rgb(102, 102, 102); font-family: Tahoma; font-size: 19px; text-indent: 35px; white-space: normal;" referrerpolicy="no-referrer"><strong><span style="text-decoration:underline;"><span style="font-family: Tahoma;line-height: 200%;color: #6666CC;letter-spacing: 0;font-size: 19px;background: #FFFFFF"><span style="font-family:Tahoma">《狂犬病疫苗》</span>(专著) 9. 狂犬病免疫球蛋白的应用</span></span></strong></a><span style="font-family: Tahoma;line-height: 200%;color: #666666;letter-spacing: 0;font-size: 19px;background: #FFFFFF"> 2021-04-13</span></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自严家新科学网博客。<br>链接地址：</label><a href="http://blog.sciencenet.cn/blog-347754-1282035.html" target="_blank" style="font-size:13px; color:#850f0f">http://blog.sciencenet.cn/blog-347754-1282035.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-347754-1281683.html" target="_black">《狂犬病疫苗》(专著) 9. 狂犬病免疫球蛋白的应用</a><br>                    <!--大赛结束-->
                                        
  
</div>
            